Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing Deep Cyclic Inhibitors, with a lead focus on atebimetinib, an oral, once-daily MEK inhibitor for MAPK pathway-driven cancers such as pancreatic cancer. This news page aggregates company announcements, clinical data updates, financing news, and other disclosures that Immuneering releases through press statements and regulatory filings.
Readers can find detailed coverage of Immuneering’s clinical trial progress, including Phase 2a data for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company has reported updated overall survival, progression-free survival, response rates, and safety findings from a cohort of 34 patients, as well as case studies of patients treated with atebimetinib plus FOLFIRINOX. Immuneering also provides timelines for anticipated milestones such as additional survival data readouts and the planned initiation of a global Phase 3 registrational trial in metastatic pancreatic cancer.
In addition to clinical results, Immuneering’s news flow includes corporate and financial updates such as quarterly financial results, underwritten public offerings of Class A common stock, private placements with institutional investors, and guidance on expected cash runway. Announcements related to index inclusion, such as the company’s expected addition to the Nasdaq Biotechnology Index, and conference presentations at healthcare and scientific meetings are also part of the regular news cycle.
Investors and followers of oncology drug development can use this page to track Immuneering’s disclosures about regulatory interactions with the FDA and EMA, combination trial agreements in non-small cell lung cancer, and intellectual property developments such as the granting of a U.S. composition of matter patent for atebimetinib. Bookmark this feed to monitor how Immuneering’s Deep Cyclic Inhibitor programs and corporate strategy evolve through official company communications.
Immuneering Corporation (Nasdaq: IMRX) announced its participation at the William Blair Biotech Focus Conference 2022 on July 13, 2022. CEO Ben Zeskind will be part of a panel discussing pre-clinical data related to the company’s lead product candidate, IMM-1-104, which targets pan-KRAS/NRAS activity in advanced solid tumors. Immuneering’s innovative approach combines translational bioinformatics with unique drug design strategies to enhance treatment outcomes for cancer patients, leveraging its proprietary 3D tumor modeling and bioinformatics platforms.
Immuneering Corporation (NASDAQ: IMRX) announced preclinical data for its dual-MEK inhibitor, IMM-1-104, showing significant tumor growth inhibition (TGI) in pancreatic cancer models with KRAS mutations. The drug demonstrated TGI of 49-84% against KRAS-G12V mutant tumors, outperforming existing treatments like sotorasib and adagrasib. The company plans to submit an IND in Q3 2022 and start Phase 1 trials in Q4 2022. These findings suggest IMM-1-104 has potential broad activity against various tumors driven by MAPK mutations, positioning it favorably in oncology.
Immuneering Corporation (NASDAQ: IMRX) will present its business strategy and pipeline at the Jefferies Healthcare Conference on June 8, 2022, and the H.C. Wainwright Global Investment Conference from May 24-26, 2022. Ben Zeskind, CEO, and Brett Hall, CSO, will lead the Jefferies presentation, which is a moderated fireside chat. The presentation will be available for live streaming and archived for 30 days. Immuneering focuses on developing oncology and neuroscience products using a unique translational bioinformatics platform, with key candidates including IMM-1-104 and IMM-6-415.
Immuneering Corporation (NASDAQ: IMRX) announced its first quarter 2022 financial results, reporting a net loss of $12.9 million ($0.49 per share). The company has $137.8 million in cash, expected to provide a runway into Q3 2024. Key developments include the anticipated IND filing for IMM-1-104 in Q3 2022 and patient enrollment in Q4 2022, with encouraging preclinical results across various tumor models. R&D expenses rose to $9.1 million, reflecting increased preclinical costs. Additionally, the second IND for IMM-6-415 is expected in 2023.
Immuneering Corporation (Nasdaq: IMRX) announced management's participation in Citi’s Biopharma VIRTUAL Co-Panel Day on May 18, 2022, focusing on software, artificial intelligence, and bioinformatics in drug development. The event will feature Ben Zeskind, Ph.D., Co-Founder and CEO, and will be webcast live at 10:00 am ET.
Immuneering aims to improve patient outcomes with a unique oncology and neuroscience pipeline. Its lead candidate, IMM-1-104, targets advanced solid tumors with RAS mutations, utilizing a proprietary 3D tumor modeling platform.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in Piper Sandler’s AI/ML Investor Conference on April 1, 2022, where CEO Ben Zeskind will discuss advancements in drug development using artificial intelligence and bioinformatics. Immuneering harnesses over a decade of experience in translational bioinformatics to enhance oncology and neuroscience therapies. Its lead candidate, IMM-1-104, is designed for treating advanced solid tumors in patients with RAS mutations by targeting the MAPK pathway. The company is also advancing other oncology and neuroscience programs.
Immuneering Corporation (Nasdaq: IMRX) announces its participation in the 21st Annual Needham Virtual Healthcare Conference, scheduled for April 11-14, 2022. Management, including CEO Ben Zeskind and CFO Biren Amin, will present insights on the company's oncology pipeline and business strategy. The presentation will occur on April 12 from 3:45-4:25 PM ET. Immuneering's lead candidate, IMM-1-104, is a dual-MEK inhibitor targeting RAS mutations in advanced tumors, aimed at sparing healthy cells. The company uses a proprietary bioinformatics platform to advance its pipeline.
Immuneering Corporation (Nasdaq: IMRX) reported financial results for Q4 and full year 2021, highlighting significant advancements in their lead product candidate, IMM-1-104. This candidate shows broad activity against various tumor models with activating mutations. The company holds $150.2 million in cash, ensuring funding through Q3 2024. Notably, they expect to file an IND for IMM-1-104 in Q3 2022. Research and development expenses increased to $26.5 million for 2021, primarily due to preclinical initiatives. The net loss for the year was $33.5 million, or $2.46 per share.
Immuneering Corporation (Nasdaq: IMRX) showcases its oncology pipeline that spares healthy cells by modulating signaling dynamics. The company will participate in two investor conferences in March 2022 to discuss its product candidates and business strategy, including a panel at the Cowen 42nd Annual Health Care Conference and a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. The lead product candidate, IMM-1-104, targets RAS mutations in advanced tumors, supported by a unique translational bioinformatics approach.
Immuneering Corporation (Nasdaq: IMRX) recently announced participation in two investor conferences to discuss its innovative oncology pipeline. The first presentation will be at the B. Riley Securities Virtual Oncology Investor Conference on January 28, 2022, at 12:00 pm ET, followed by a Guggenheim Virtual Oncology Conference on February 9, 2022, at 10:00 am ET. The company's proprietary pipeline focuses on oncology and neuroscience drug candidates designed to target tumor cells while sparing healthy cells. These insights stem from a robust translational bioinformatics platform.